Detail A new epitope peptide derived from hepatitis C virus 1b possessing the capacity to induce cytotoxic T-lymphocytes in HCV1b-infected patients with HLA-A11, - A31, and A-33 (from Cancer Immunol Immunother 2007, 56, 1359-1366) Bibliografi Author: Matsueda, Satoko ; Yamada, Akira ; Takao, Yukari ; Tamura, Mayumi ; Koumatsu, Nobukazu ; Yutani, Shigeru ; Ide, Tatsuya ; Sata, Michio ; Itoh, Kyogo Topik: Hepatitis; HCV; Peptide vaccine; CTL; Epitope; HLA-A3; Validation ref - 4 Bahasa: (EN )     Penerbit: Springer-Verlag     Tahun Terbit: 2007     Jenis: Article - diterbitkan di jurnal ilmiah internasional Fulltext: art_3A10.1007_2Fs00262-007-0284-5.pdf (445.5KB; 1 download) Abstract Background Hepatitis C virus (HCV) frequently causes chronic hepatitis, cirrhosis, and hepatocellular carcinoma after long-term persistent infection. Among various genotypes of HCV, HCV1b is resistant to standard interferon therapy, and thus the development of new treatment modality is needed. Results To provide a scientiWc basis for specific immunotherapy for HCV1b, we investigated HCV1b-derived epitope peptides recognized by human leukocyte antigen (HLA)-A11, -A31, or -A33-restricted cytotoxic T-lymphocytes (CTLs), and report here three novel vaccine candidate peptides selected by both antibody screening and CTL-inducing capacity from among 46 peptides of conserved regions of HCV1b sequences with binding motifs to HLA-A11, -A31, and -A33. Significant levels of IgG reactive to each of the three peptides were detected in the plasma of more than 50% of the HCV1b+ patients. One peptide at positions 30–39 of the core protein induced peptide-specific CTLs from peripheral blood mononuclear cells (PBMCs) of HLA-A11+, -A31+, and -A33+ patients. The other two peptides at positions 35–43 of the core protein and at positions 918–926 of the non-structural protein 2 also induced peptide-specific CTLs from the PBMCs of HLA-A11+ and -A33+ patients. Conclusion Therefore, the peptide at positions 30–39 of the core protein could be an appropriate target molecule of specific immunotherapy for all HLA-A11+, -A31+, and -A33+ patients with HCV1b-related diseases. [validation ref - 4] Opini Anda Klik untuk menuliskan opini Anda tentang koleksi ini! Lihat Sejarah Pengadaan  Konversi Metadata   Kembali

Copyright © 2006, 2007 Unika Atma Jaya, all rights reserved